Ian Sanne to Lipids
This is a "connection" page, showing publications Ian Sanne has written about Lipids.
Connection Strength
0,051
-
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):18-29.
Score: 0,051